Next Article in Journal
Composition of Challenge Substance in Standardized Antimicrobial Efficacy Testing of Wound Antimicrobials Is Essential to Correctly Simulate Efficacy in the Human Wound Micro-Environment
Next Article in Special Issue
Odontogenic Chronic Rhinosinusitis: Structured Histopathology Evidence in Different Patho-Physiological Mechanisms
Previous Article in Journal
Affinity Capture Elution (ACE) ELISA Method Development and Validation for Novel RPH-104 Drug Immunogenicity Evaluation
Previous Article in Special Issue
Medical Records: A Historical Narrative
 
 
Article
Peer-Review Record

Potential Effects of Non-Surgical Periodontal Therapy on Periodontal Parameters, Inflammatory Markers, and Kidney Function Indicators in Chronic Kidney Disease Patients with Chronic Periodontitis

Biomedicines 2022, 10(11), 2752; https://doi.org/10.3390/biomedicines10112752
by Ahmed Chaudhry 1,2, Nur Karyatee Kassim 2,3,4,*, Siti Lailatul Akmar Zainuddin 1,2, Haslina Taib 1,2, Hanim Afzan Ibrahim 2,3,4, Basaruddin Ahmad 2,5, Muhammad Hafiz Hanafi 2,6 and Azreen Syazril Adnan 7
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Biomedicines 2022, 10(11), 2752; https://doi.org/10.3390/biomedicines10112752
Submission received: 23 September 2022 / Revised: 13 October 2022 / Accepted: 18 October 2022 / Published: 29 October 2022
(This article belongs to the Special Issue 10th Anniversary of Biomedicines—Biomarkers in Pain)

Round 1

Reviewer 1 Report

This study investigated the effect of  non-surgical periodontal therapy (NSPT) on periodontal parameters, inflammatory markers, and kidney function indicators in chronic kidney disease (CKD) patients with chronic periodontitis. Although the findings is interesting, I haver several concerns about this study.

1. The study site and the method of patients enrollment were not mentioned. In addition, a figure to show the alogrithm of patients enrollment is needed.

2. Please describe the method of NSPT in the method section.

3. Please add some possible confounding factors, such as statin, corticosteroid which could affect the inflammation markes.

Author Response

Dear reviewer,

Thank you for your valuable comments. We have revised the manuscript accordingly.  Please see the attachment.

Thank you

Author Response File: Author Response.pdf

Reviewer 2 Report

In general, this work is really interesting and well written. My comments aim to increase the scientific soundness and clarity of it.

 

Line 8 – please correct affiliations (add departments)

Line 84 – short description of methodology applied should follow the goals.

Line 128 – from which vessel blood samples were collected ?

Line 140 – please provide country of origin for COBAS/Architect hardware

Line 147 – what was post-hoc test in ANOVA? What P-value was considered statistically significant?

Line 264 – please explain what TNF alfa stands for.

Author Response

Dear reviewer,

Thank you for your valuable comments. We have revised the manuscript accordingly.  Please see the attachment.

Thank you

Author Response File: Author Response.pdf

Reviewer 3 Report

1. Glycaemic control with definition of HbA1c < 7% is very tight controlled, it is not "good" controlled. Nowadays, we do not suggest A1C <7% in CKD patients. Good is subjective, not objective.

2. Flowchart of inclusion and exclusion should be provided to get the total amount of patients that finally included.

3. How many patients had CKD stage 3A, stage 3B, and stage 4?

4. Serum urea is not correct term. BUN?

5. All abbreviations should be provided below all figures and tables

6. What are implications and future directions, please add in the discussion.

Author Response

Dear reviewer,

Thank you for your valuable comments. We have revised the manuscript accordingly.  Please see the attachment.

Thank you

Author Response File: Author Response.pdf

Round 2

Reviewer 1 Report

The authors response well, so I have no more suggestion.

Back to TopTop